SPOTLIGHT -
Dr Clark is the founder and CEO of Terran Biosciences.
Much Ado About Something: Why There’s Excitement Behind Novel Mechanism of Action in Schizophrenia
Why are experts excited about KarXT, a novel muscarinic acetylcholine receptor agonist that, if approved, is poised to revolutionize schizophrenia treatment?
TerXT: Combination of Xanomeline and Trospium Prodrugs for Schizophrenia
Sam Clark, MD, PhD, the founder and CEO of Terran Biosciences shared all you need to know about the development of their schizophrenia treatment, TerXT.